Nanoform Finland Plc
Nanoform Finland Oyj engages in the provision of nanotechnology and drug particle engineering services for the pharma and biotech industries in Europe and the United States. The company provides nanoforming technologies, formulation, and analytical services, including controlled expansion of supercritical solutions technology that enables the creation of active pharmaceutical ingredients (API) na… Read more
Nanoform Finland Plc (NANOFH) - Net Assets
Latest net assets as of September 2025: €44.58 Million EUR
Based on the latest financial reports, Nanoform Finland Plc (NANOFH) has net assets worth €44.58 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€57.13 Million) and total liabilities (€12.56 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €44.58 Million |
| % of Total Assets | 78.02% |
| Annual Growth Rate | 96.12% |
| 5-Year Change | -4.16% |
| 10-Year Change | N/A |
| Growth Volatility | 259.63 |
Nanoform Finland Plc - Net Assets Trend (2016–2024)
This chart illustrates how Nanoform Finland Plc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Nanoform Finland Plc (2016–2024)
The table below shows the annual net assets of Nanoform Finland Plc from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €60.03 Million | -10.33% |
| 2023-12-31 | €66.95 Million | -23.24% |
| 2022-12-31 | €87.21 Million | +3.22% |
| 2021-12-31 | €84.49 Million | +34.90% |
| 2020-12-31 | €62.64 Million | +689.67% |
| 2019-12-31 | €7.93 Million | +57.58% |
| 2018-12-31 | €5.03 Million | +2138.14% |
| 2017-12-31 | €-246.96K | -190.03% |
| 2016-12-31 | €274.31K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Nanoform Finland Plc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 10730067000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €80.00K | 0.13% |
| Other Comprehensive Income | €167.65 Million | 279.26% |
| Total Equity | €60.03 Million | 100.00% |
Nanoform Finland Plc Competitors by Market Cap
The table below lists competitors of Nanoform Finland Plc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
209640
KQ:209640
|
$49.39 Million |
|
Tze Shin International Co Ltd
TW:2611
|
$49.39 Million |
|
TaiRx, Inc.
TWO:6580
|
$49.39 Million |
|
Mostostal Zabrze - Holding SA
WAR:MSZ
|
$49.40 Million |
|
ONEJOON Co. Ltd.
KQ:382840
|
$49.37 Million |
|
Rising Dragon Acquisition Corp.
NASDAQ:RDACU
|
$49.36 Million |
|
0JR0
LSE:0JR0
|
$49.36 Million |
|
Super Dragon Technology Co Ltd
TW:9955
|
$49.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Nanoform Finland Plc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 66,946,594 to 60,031,670, a change of -6,914,924 (-10.3%).
- Net loss of 23,427,927 reduced equity.
- Share repurchases of 15,587,350 reduced equity.
- New share issuances of 15,587,351 increased equity.
- Other comprehensive income increased equity by 14,995,440.
- Other factors increased equity by 1,517,562.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-23.43 Million | -39.03% |
| Share Repurchases | €15.59 Million | -25.97% |
| Share Issuances | €15.59 Million | +25.97% |
| Other Comprehensive Income | €15.00 Million | +24.98% |
| Other Changes | €1.52 Million | +2.53% |
| Total Change | €- | -10.33% |
Book Value vs Market Value Analysis
This analysis compares Nanoform Finland Plc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.85x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €-0.01 | €0.61 | x |
| 2018-12-31 | €0.12 | €0.61 | x |
| 2019-12-31 | €0.20 | €0.61 | x |
| 2020-12-31 | €1.11 | €0.61 | x |
| 2021-12-31 | €1.24 | €0.61 | x |
| 2022-12-31 | €1.13 | €0.61 | x |
| 2023-12-31 | €0.85 | €0.61 | x |
| 2024-12-31 | €0.72 | €0.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Nanoform Finland Plc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -39.03%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -843.49%
- • Asset Turnover: 0.04x
- • Equity Multiplier: 1.20x
- Recent ROE (-39.03%) is below the historical average (-35.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | -801.96% | 0.08x | 0.00x | €-496.58K |
| 2018 | -41.21% | -882.67% | 0.03x | 1.63x | €-2.58 Million |
| 2019 | -96.98% | -15669.26% | 0.00x | 1.63x | €-8.49 Million |
| 2020 | -31.04% | -2830.92% | 0.01x | 1.18x | €-25.70 Million |
| 2021 | -23.30% | -1007.38% | 0.02x | 1.18x | €-28.14 Million |
| 2022 | -25.31% | -632.99% | 0.03x | 1.15x | €-30.80 Million |
| 2023 | -31.00% | -808.73% | 0.03x | 1.17x | €-27.45 Million |
| 2024 | -39.03% | -843.49% | 0.04x | 1.20x | €-29.43 Million |
Industry Comparison
This section compares Nanoform Finland Plc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $-243,000
- Average return on equity (ROE) among peers: 0.00%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Nanoform Finland Plc (NANOFH) | €44.58 Million | 0.00% | 0.28x | $49.39 Million |
| Herantis Pharma Oyj (HRTIS) | $-243.00K | 0.00% | 0.00x | $33.60 Million |